Literature DB >> 11316764

Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines.

J W Tomlinson1, J Moore, M S Cooper, I Bujalska, M Shahmanesh, C Burt, A Strain, M Hewison, P M Stewart.   

Abstract

Patients with glucocorticoid excess develop central obesity, yet in simple obesity, circulating glucocorticoid levels are normal. We have suggested that the increased activity and expression of the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) generating active cortisol from cortisone within adipose tissue may be crucial in the pathogenesis of obesity. In this study primary cultures of human hepatocytes and adipose stromal cells (ASC) were used as in vitro models to investigate the tissue-specific regulation of 11betaHSD1 expression and activity. Treatment with tumor necrosis factor-alpha (TNFalpha) caused a dose-dependent increase in 11betaHSD1 activity in primary cultures of both sc [1743.1 +/- 1015.4% (TNFalpha, 10 ng/ml); P < 0.05 vs. control (100%)] and omental [375.8 +/- 57.0% (TNFalpha, 10 ng/ml); P < 0.01 vs. control (100%)] ASC, but had no effect on activity in human hepatocytes [90.2 +/- 2.8% (TNFalpha, 10 ng/ml); P = NS vs. control (100%)]. Insulin-like growth factor I (IGF-I) caused a dose-dependent inhibition of 11betaHSD1 activity in sc [49.7 +/- 15.0% (IGF-I, 100 ng/ml]; P < 0.05 vs. control (100%)] and omental [71.6 +/- 7.5 (IGF-I, 100 ng/ml); P < 0.01 vs. control (100%)] stromal cells, but not in human hepatocytes [101.8 +/- 15.7% (IGF-I, 100 ng/ml); P = NS vs. control (100%)]. Leptin treatment did not alter 11betaHSD1 activity in human hepatocytes, but increased activity in omental ASC [135.8 +/- 14.1% (leptin, 100 ng/ml); P = 0.08 vs. control (100%)]. Treatment with interleukin-1beta induced 11betaHSD1 activity and expression in sc and omental ASC in a time- and dose-dependent manner. 15-Deoxy-12,14-PGJ2, the putative endogenous ligand of the orphan nuclear receptor peroxisome proliferator-gamma, significantly increased 11betaHSD1 activity in omental cells [179.7 +/- 29.6% (1 microM); P < 0.05 vs. control (100%)] and sc [185.3 +/- 12.6% (1 microM); P < 0.01 vs. control (100%)] ASC, and it is possible that expression of this ligand may ensure continued cortisol generation to permit adipocyte differentiation. Protease inhibitors used in the treatment of human immunodeficiency virus infection are known to cause a lipodystrophic syndrome and central obesity, but saquinavir, indinavir, and neflinavir caused a dose-dependent inhibition of 11betaHSD1 activity in primary cultures of human omental ASC. 11betaHSD1 expression is increased in human adipose tissue by TNFalpha, interleukin-1beta, leptin, and orphan nuclear receptor peroxisome proliferator-gamma agonists, but is inhibited by IGF-I. This autocrine and/or paracrine regulation is tissue specific and explains recent clinical data and animal studies evaluating cortisol metabolism in obesity. Tissue-specific 11betaHSD1 regulation offers the potential for selective enzyme inhibition within adipose tissue as a novel therapy for visceral obesity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11316764     DOI: 10.1210/endo.142.5.8168

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  61 in total

Review 1.  Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity.

Authors:  Deborah J Wake; Brian R Walker
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

Review 2.  [Adverse effects of antiretroviral therapy. Aspects of pathogenesis].

Authors:  U Seybold; R Draenert; F D Goebel
Journal:  Internist (Berl)       Date:  2003-06       Impact factor: 0.743

Review 3.  What does irritable bowel syndrome share with non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Matteo Nicola Dario Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

Review 4.  Tissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 and pathogenesis of the metabolic syndrome.

Authors:  P Putignano; F Pecori Giraldi; F Cavagnini
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

Review 5.  The overtraining syndrome in athletes: a stress-related disorder.

Authors:  A Angeli; M Minetto; A Dovio; P Paccotti
Journal:  J Endocrinol Invest       Date:  2004-06       Impact factor: 4.256

Review 6.  Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism.

Authors:  Eliza B Geer; Julie Islam; Christoph Buettner
Journal:  Endocrinol Metab Clin North Am       Date:  2014-03       Impact factor: 4.741

Review 7.  Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

Authors:  J A P Da Silva; J W G Jacobs; J R Kirwan; M Boers; K G Saag; L B S Inês; E J P de Koning; F Buttgereit; M Cutolo; H Capell; R Rau; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2005-08-17       Impact factor: 19.103

Review 8.  Neuroendocrine-immune interactions in rheumatoid arthritis: mechanisms of glucocorticoid resistance.

Authors:  Marni N Silverman; Esther M Sternberg
Journal:  Neuroimmunomodulation       Date:  2008-07-29       Impact factor: 2.492

Review 9.  Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient.

Authors:  Charmaine D Rochester; Oluwaranti Akiyode
Journal:  World J Diabetes       Date:  2014-06-15

10.  Depot-specific regulation of the conversion of cortisone to cortisol in human adipose tissue.

Authors:  Mi-Jeong Lee; Susan K Fried; Steven S Mundt; Yanxin Wang; Sean Sullivan; Alice Stefanni; Bruce L Daugherty; Anne Hermanowski-Vosatka
Journal:  Obesity (Silver Spring)       Date:  2008-04-03       Impact factor: 5.002

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.